Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Endometriosis Market by Type (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drugs, Progestin, Oral Contraceptive Pills), By Application (Hospital Use, Clinic Use, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Endometriosis Market by Type (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drugs, Progestin, Oral Contraceptive Pills), By Application (Hospital Use, Clinic Use, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 189611 3300 Pharma & Healthcare 377 238 Pages 4.6 (33)
                                          

Endometriosis is a chronic, inflammatory disease that affects the uterus and other pelvic organs. It is characterized by the presence of endometrial tissue outside of the uterus, which can lead to pain and infertility. The global endometriosis market was valued at USD 3.2 billion in 2018 and is expected to reach USD 4.5 billion by 2030, growing at a CAGR of 5.6% from 2019 to 2030. Gonadotropins releasing hormone agonists (GnRH-a) are expected to be the fastest-growing segment during the forecast period due to their efficacy in treating endometriosis symptoms such as pain and infertility caused by this condition. The global endometriosis market has been segmented on the basis of type into gonadotropins releasing hormone agonists (GnRH-a), nonsteroidal antiinflammatory drugs (NSAIDs), progestin, oral contraceptive pills; on application into hospital use and clinic use; and on region into North America, Latin America, Europe, Asia Pacific & Middle East & Africa regions respectively for better understanding of this market across different geographies with respect to various segments such as type, application etc, along with their respective growth rates over time for each region/segment from 2021-2030. 5a) The use of hormonal birth control methods has been linked to an increase in risk for developing endometriosis; however, it can also be used as a treatment option for those diagnosed with this condition by suppressing ovulation or preventing implantation on the uterine wall (depending on type). 5b) Hormonal birth control methods can also be used to treat symptoms associated with endometriosis such as pain during menstruation or pelvic pain by reducing inflammation and relieving pressure on pelvic organs that may cause discomfort during periods or sex (depending on type).

  1. The number of women with endometriosis is increasing.
  2. Women are delaying childbirth and having children later in life, which increases the risk of endometriosis.
  3. Endometriosis is more common in women who have had a hysterectomy or tubal ligation, which has increased the number of people with endometriosis over time as well as the number of people who are infertile due to these surgeries.
  4. There is an increased awareness about endometriosis and its symptoms, which may lead to more diagnoses and treatment options for patients with this condition.

Industry Growth Insights published a new data on “Endometriosis Market”. The research report is titled “Endometriosis Market research by Types (Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drugs, Progestin, Oral Contraceptive Pills), By Applications (Hospital Use, Clinic Use, Other), By Players/Companies AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, EndoCeutics, Euroscreen, Forendo Pharma, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, Takeda, Bayer AG, Neurocrine Biosciences”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Endometriosis Market Research Report

By Type

Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drugs, Progestin, Oral Contraceptive Pills

By Application

Hospital Use, Clinic Use, Other

By Companies

AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, EndoCeutics, Euroscreen, Forendo Pharma, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, Takeda, Bayer AG, Neurocrine Biosciences

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

238

Number of Tables & Figures

167

Customization Available

Yes, the report can be customized as per your need.


Global Endometriosis Industry Outlook


Global Endometriosis Market Report Segments:

The global Endometriosis market is segmented on the basis of:

Types

Gonadotropins Releasing Hormone Agonists, Non-Steroidal Anti-Inflammatory Drugs, Progestin, Oral Contraceptive Pills

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospital Use, Clinic Use, Other

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. AbbVie
  2. AstraZeneca
  3. Bayer HealthCare
  4. Pfizer
  5. Addex Therapeutics
  6. Astellas Pharma
  7. Debiopharm
  8. ElexoPharm
  9. EndoCeutics
  10. Euroscreen
  11. Forendo Pharma
  12. Kissei Pharmaceutical
  13. Neurocrine Biosciences
  14. Nippon Shinyaku
  15. Takeda
  16. Bayer AG
  17. Neurocrine Biosciences

Global Endometriosis Market Overview


Highlights of The Endometriosis Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Gonadotropins Releasing Hormone Agonists
    2. Non-Steroidal Anti-Inflammatory Drugs
    3. Progestin
    4. Oral Contraceptive Pills
  1. By Application:

    1. Hospital Use
    2. Clinic Use
    3. Other
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Endometriosis Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Endometriosis Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Endometriosis is a condition in which the tissue that lines the inside of the uterus (the endometrium) grows outside of it. This growth can occur anywhere on or near the uterine wall, including within and around the fallopian tubes. The endometrium can also grow on other parts of your body, such as your ovaries or bladder.

Some of the key players operating in the endometriosis market are AbbVie, AstraZeneca, Bayer HealthCare, Pfizer, Addex Therapeutics, Astellas Pharma, Debiopharm, ElexoPharm, EndoCeutics, Euroscreen, Forendo Pharma, Kissei Pharmaceutical, Neurocrine Biosciences, Nippon Shinyaku, Takeda, Bayer AG, Neurocrine Biosciences.

The endometriosis market is expected to register a CAGR of 5.6%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Endometriosis Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Endometriosis Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Endometriosis Market - Supply Chain
   4.5. Global Endometriosis Market Forecast
      4.5.1. Endometriosis Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Endometriosis Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Endometriosis Market Absolute $ Opportunity

5. Global Endometriosis Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Endometriosis Market Size and Volume Forecast by Type
      5.3.1. Gonadotropins Releasing Hormone Agonists
      5.3.2. Non-Steroidal Anti-Inflammatory Drugs
      5.3.3. Progestin
      5.3.4. Oral Contraceptive Pills
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Endometriosis Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Endometriosis Market Size and Volume Forecast by Application
      6.3.1. Hospital Use
      6.3.2. Clinic Use
      6.3.3. Other
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Endometriosis Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Endometriosis Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Endometriosis Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Endometriosis Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Endometriosis Demand Share Forecast, 2019-2026

9. North America Endometriosis Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Endometriosis Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Endometriosis Market Size and Volume Forecast by Application
      9.4.1. Hospital Use
      9.4.2. Clinic Use
      9.4.3. Other
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Endometriosis Market Size and Volume Forecast by Type
      9.7.1. Gonadotropins Releasing Hormone Agonists
      9.7.2. Non-Steroidal Anti-Inflammatory Drugs
      9.7.3. Progestin
      9.7.4. Oral Contraceptive Pills
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Endometriosis Demand Share Forecast, 2019-2026

10. Latin America Endometriosis Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Endometriosis Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Endometriosis Market Size and Volume Forecast by Application
      10.4.1. Hospital Use
      10.4.2. Clinic Use
      10.4.3. Other
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Endometriosis Market Size and Volume Forecast by Type
      10.7.1. Gonadotropins Releasing Hormone Agonists
      10.7.2. Non-Steroidal Anti-Inflammatory Drugs
      10.7.3. Progestin
      10.7.4. Oral Contraceptive Pills
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Endometriosis Demand Share Forecast, 2019-2026

11. Europe Endometriosis Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Endometriosis Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Endometriosis Market Size and Volume Forecast by Application
      11.4.1. Hospital Use
      11.4.2. Clinic Use
      11.4.3. Other
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Endometriosis Market Size and Volume Forecast by Type
      11.7.1. Gonadotropins Releasing Hormone Agonists
      11.7.2. Non-Steroidal Anti-Inflammatory Drugs
      11.7.3. Progestin
      11.7.4. Oral Contraceptive Pills
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth rojections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Endometriosis Demand Share, 2019-2026

12. Asia Pacific Endometriosis Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Endometriosis Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Endometriosis Market Size and Volume Forecast by Application
      12.4.1. Hospital Use
      12.4.2. Clinic Use
      12.4.3. Other
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Endometriosis Market Size and Volume Forecast by Type
      12.7.1. Gonadotropins Releasing Hormone Agonists
      12.7.2. Non-Steroidal Anti-Inflammatory Drugs
      12.7.3. Progestin
      12.7.4. Oral Contraceptive Pills
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Endometriosis Demand Share, 2019-2026

13. Middle East & Africa Endometriosis Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Endometriosis Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Endometriosis Market Size and Volume Forecast by Application
      13.4.1. Hospital Use
      13.4.2. Clinic Use
      13.4.3. Other
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Endometriosis Market Size and Volume Forecast by Type
      13.7.1. Gonadotropins Releasing Hormone Agonists
      13.7.2. Non-Steroidal Anti-Inflammatory Drugs
      13.7.3. Progestin
      13.7.4. Oral Contraceptive Pills
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Endometriosis Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Endometriosis Market: Market Share Analysis
   14.2. Endometriosis Distributors and Customers
   14.3. Endometriosis Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. AbbVie
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. AstraZeneca
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Bayer HealthCare
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Pfizer
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Addex Therapeutics
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Astellas Pharma
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Debiopharm
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. ElexoPharm
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. EndoCeutics
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Euroscreen
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Forendo Pharma
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Kissei Pharmaceutical
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Neurocrine Biosciences
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. Nippon Shinyaku
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. Takeda
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. Bayer AG
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. Neurocrine Biosciences
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us